PHASE I STUDY OF PHOTODYNAMIC THERAPY FOR SURFACE MALIGNANCIES

光动力疗法涉及使用一种光激活化合物，该化合物 定位在肿瘤中，然后用光激活这种化合物 用于治疗癌症的细胞毒作用。当前的协议 使用Photofrin II制剂的静脉给药 血卟啉衍生物，目前唯一被批准的光敏剂 在人类身上使用。这之后是向受影响的人传递光 使用光纤耦合到氩/泵浦的染料激光器的区域。 血卟啉衍生物在肿瘤中的选择性定位 某些正常组织。光敏剂在水溶液中的选择性保留 与聚焦光线投射到相关区域许可证相结合 对正常组织影响最小的选择性肿瘤毁损术 组织。血卟啉衍生物光动力疗法可能在临床上应用 可用于肿瘤涉及的多个解剖部位。

Photodynamic therapy involves the use of a light activated compound which localizes in tumor, followed by the activation of this compound by light for cytotoxic effects for the treatment of cancer. The current protocol uses the intravenous administration of the Photofrin II preparation of the hematoporphyrin derivative, the only currently approved photosensitizer for use in humans. This is followed by the delivery of light to the affected area using optical fibers coupled to an argon/pumped dye laser. Hematoporphyrin derivative selectively localizes in tumor compared to certain normal tissues. Selective retention of the photosensitizer in combination with focal light delivery to the involved area permits selective destruction of tumor with minimal effect on uninvolved normal tissue. Hematoporphyrin derivative photodynamic therapy may be clinically useful in a number of anatomic sites involved by tumor.